Evidence map›Paper›PMID 31659868›Full record

ArticleInternational journal of rheumatic diseases2019

Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo

Sanchita Raychaudhuri, Christine Abria, Zachary T Harmany, Charles M Smith, Smriti Kundu-Raychaudhuri, Siba P Raychaudhuri, Abhijit J Chaudhari

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of rheumatic diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Diagnostics (Basel, Switzerland) · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Sanchita RaychaudhuriCenter for Molecular and Genomic Imaging, University of California Davis, Davis, CA, USA.
Christine AbriaVeterans Affairs Medical Center, Mather, CA, USA.
Zachary T HarmanyCenter for Molecular and Genomic Imaging, University of California Davis, Davis, CA, USA.
Charles M SmithCenter for Molecular and Genomic Imaging, University of California Davis, Davis, CA, USA.
Smriti Kundu-RaychaudhuriVeterans Affairs Medical Center, Mather, CA, USA.
Siba P RaychaudhuriVeterans Affairs Medical Center, Mather, CA, USA.
Abhijit J ChaudhariCenter for Molecular and Genomic Imaging, University of California Davis, Davis, CA, USA.ORCID https://orcid.org/0000-0002-4211-1900
Veterans Health Administration · USUniversity of California, Davis · US

Funding

Total-Body PET/CT for assessing Rheumatoid Arthritis Disease Activity and Treatment ResponseR01AR076088 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHAUDHARI, ABHIJIT J · 2019 to 2021
$617k
NIAMS NIH HHS R01 AR076088NIH HHS R01 AR076088Pfizer Inc New York
6 · The paper itself

Abstract

purposeTo assess the capability of in vivo positron emission tomography (PET) using

methodsTwenty-four mice with collagen-induced arthritis in the following groups were assessed: Group 1, where the changes in PET measures for the extremity joints were evaluated at the peak and trough plasma drug levels after administration of a single dose of tofacitinib (4 hours apart); Group 2, where joint PET measures were assessed before treatment and after 6 days of administration of a daily dose of tofacitinib; and group 3 (controls), where joint PET measures were derived from the same mice, 6 days apart.

resultsAt about peak plasma levels of the drug after a single tofacitinib administration, there was a reduction in PET measures compared to pretreatment values, suggesting decreased inflammatory activity. These measures were equivalent to those obtained after 6 days of daily dosing by tofacitinib. However, PET measures at trough plasma levels of the drug from tofacitinib administration were significantly higher than those at peak plasma drug levels and equivalent to pretreatment measures. There were insignificant changes in PET measures for the control animals.

conclusion

Indexed as

Positron-Emission TomographyAnimalsAntirheumatic AgentsArthritis, ExperimentalArthritis, RheumatoidDrug Administration ScheduleFluorodeoxyglucose F18Janus Kinase InhibitorsJointsMaleMice, Inbred DBAPiperidinesPredictive Value of TestsPyrimidinesPyrrolesRadiopharmaceuticalsAntirheumatic AgentsFluorodeoxyglucose F18Janus Kinase InhibitorsPiperidinesPyrimidinesPyrrolesRadiopharmaceuticalstofacitinib18F-FDGcollagen-induced arthritisJanus kinase inhibitorjoint inflammationpositron emission tomographytofacitinib

Identifiers

PMID31659868
PMCPMC6935681
OpenAlexW2982381505

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.